MAP2K7 and metastatic melanoma: BRAF inhibitor with or without MEK inhibitor for treatment of unresectable or metastatic melanoma and metastatic non-small cell lung cancer with BRAF(V600E) mutation were approved by the U.S. Food and Drug Administration [43].